Ionis Pharmaceuticals Inc (NASDAQ:IONS) was the target of some unusual options trading activity on Thursday. Stock investors purchased 2,727 put options on the stock. This represents an increase of approximately 1,180% compared to the average daily volume of 213 put options.
Ionis Pharmaceuticals (NASDAQ:IONS) opened at $53.22 on Tuesday. The company has a market cap of $6,620.00, a price-to-earnings ratio of 380.14 and a beta of 2.86. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25. Ionis Pharmaceuticals has a 12-month low of $37.26 and a 12-month high of $65.51.
In related news, Chairman Stanley T. Crooke sold 22,000 shares of the stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $50.01, for a total transaction of $1,100,220.00. Following the completion of the sale, the chairman now owns 58,014 shares in the company, valued at approximately $2,901,280.14. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO B Lynne Parshall sold 16,118 shares of the stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $65.00, for a total transaction of $1,047,670.00. Following the sale, the chief operating officer now owns 33,526 shares of the company’s stock, valued at approximately $2,179,190. The disclosure for this sale can be found here. In the last 90 days, insiders sold 102,781 shares of company stock valued at $5,733,330. Company insiders own 2.13% of the company’s stock.
IONS has been the subject of a number of recent research reports. Barclays decreased their price target on shares of Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating for the company in a research note on Thursday, September 21st. BMO Capital Markets reiterated an “outperform” rating and set a $69.00 price target on shares of Ionis Pharmaceuticals in a research note on Monday, October 2nd. Goldman Sachs Group reiterated a “sell” rating and set a $30.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 6th. Stifel Nicolaus reiterated a “hold” rating and set a $50.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Finally, Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 price target for the company in a research note on Tuesday, October 17th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. Ionis Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $50.76.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2018/01/16/traders-purchase-large-volume-of-ionis-pharmaceuticals-put-options-ions.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
What are top analysts saying about Ionis Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ionis Pharmaceuticals and related companies.